Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

TTRX

Turn Therapeutics Inc

Oct 24 • 04:00PM ET

5.08

+0.13 2.63 %

Healthcare • Biotechnology • USA • NASD

Index	-	P/E	-	EPS (ttm)	-0.13	Insider Own	67.52%	Shs Outstand	14.01M	Perf Week	0.40%
Market Cap	142.34M	Forward P/E	-	EPS next Y	-	Insider Trans	0.13%	Shs Float	9.10M	Perf Month	-
Enterprise Value	139.25M	PEG	-	EPS next Q	-	Inst Own	0.19%	Short Float	-	Perf Quarter	-
Income	-1.77M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Sales	0.00M	P/B	29.39	EPS next Y	-	ROA	-87.36%	Short Interest	-	Perf YTD	-27.43%
Book/sh	0.17	P/C	44.62	EPS next 5Y	-	ROE	-	52W High	26.50 -80.83%	Perf Year	-
Cash/sh	0.11	P/FCF	-	EPS past 3/5Y	36.36% -	ROIC	-71.31%	52W Low	4.07 24.82%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	14.32% -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	42.98%	Oper. Margin	-	ATR (14)	2.59	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.20	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	-	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	3.20	EPS Q/Q	-	SMA20	-12.90%	Beta	-	Target Price	-
Payout	-	Debt/Eq	0.04	Sales Q/Q	-	SMA50	-12.90%	Rel Volume	0.15	Prev Close	4.95
Employees	-	LT Debt/Eq	0.02	Earnings	-	SMA200	-12.90%	Avg Volume	1.96M	Price	5.08
IPO	Oct 08, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	286,185	Change	2.63%

Oct-22-25 08:00AM	Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones (GlobeNewswire) -11.81%
Oct-20-25 08:22AM	Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025 (GlobeNewswire)
Oct-15-25 08:00AM	Turn Therapeutics Appoints Dr. Kent Kester to Board of Directors (GlobeNewswire) -14.57%
Oct-14-25 12:07PM	Turn Therapeutics Appoints Arthur Golden to Board of Directors (GlobeNewswire) -8.29%
Oct-08-25 08:00AM	Turn Therapeutics to Commence Trading Today on Nasdaq (GlobeNewswire)

Turn Therapeutics, Inc. is a pharmaceutical and medical device development company. Its primary development programs focus on dermatological diseases. The company was founded on January 6, 2015 and is headquartered in Westlake Village, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chaudhary Zuraiz	See Remarks	Oct 23 '25	Buy	4.95	5,050	24,998	5,050	Oct 23 09:03 PM
GOLDEN ARTHUR F	Director	Oct 23 '25	Buy	4.95	20,202	100,000	30,202	Oct 23 09:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TTRX

Turn Therapeutics Inc

Upgrade your FINVIZ experience